Orexin receptor antagonists: a new concept in CNS disorders?
Gatfield
John
J
Drug Discovery Biology, Actelion Pharmaceuticals Ltd, Allschwil/BL, Switzerland.
Brisbare-Roch
Catherine
C
Jenck
Francois
F
Boss
Christoph
C
D000081:Acetamides / Q000737:chemistry / Q000627:therapeutic use; D001381:Azepines / Q000737:chemistry / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism / Q000502:physiology; D007546:Isoquinolines / Q000737:chemistry / Q000627:therapeutic use; D009479:Neuropeptides / Q000378:metabolism / Q000502:physiology; D064446:Orexin Receptors; D000068797:Orexins; D010330:Patents as Topic; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018013:Receptors, Neuropeptide / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction; D014230:Triazoles / Q000737:chemistry / Q000627:therapeutic use
D000081:Acetamides; D001381:Azepines; D047908:Intracellular Signaling Peptides and Proteins; D007546:Isoquinolines; D009479:Neuropeptides; D064446:Orexin Receptors; D000068797:Orexins; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide; D014230:Triazoles; C551624:suvorexant; C519150:almorexant